rcca-header
Clinical Trials

A Randomized, Phase 3, open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Platinum-Based Doublet Chemotherapy, and Ipilimumab (ANTI-CTLA-4 Antibody), Versus Pembrolizumab Monotherapy in First-line treatment of patients with Advanced or metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 equals to or greater than 50%

Type of Cancer
Lung
Phase
Division (Location)
Bethesda, MD
Study ID
NCT#
Brief Description
A Randomized, Phase 3, open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Platinum-Based Doublet Chemotherapy, and Ipilimumab (ANTI-CTLA-4 Antibody), Versus Pembrolizumab Monotherapy in First-line treatment of patients with Advanced or metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 equals to or greater than 50%

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.